Donepezil Hydrochloride Tablet
Product Images NDC 71335-2436

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Donepezil Hydrochloride (NDC 71335-2436). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure 1. Time-course Of The Change From Baseline In Adas-cog Score For Patients Completing 24 Weeks Of Treatment. (Donepezil Fig1)

Figure 1. Time-course Of The Change From Baseline In Adas-cog Score For Patients Completing 24 Weeks Of Treatment. (Donepezil Fig1)
A line graph showing the mean change from baseline in ADAS-cog scores over 30 weeks of drug treatment comparing Donepezil Hydrochloride 10 mg/day, Donepezil Hydrochloride 5 mg/day, and placebo. The graph depicts clinical improvement and decline along the vertical axis, with data points and error bars for each treatment group across time.*
FDA Label Image

Figure 10. Cumulative Percentage Of Patients Completing 6 Months Of Double-blind Treatment With Particular Changes From Baseline In Adcs-adl-severe Scores. (Donepezil Fig10)

Figure 10. Cumulative Percentage Of Patients Completing 6 Months Of Double-blind Treatment With Particular Changes From Baseline In Adcs-adl-severe Scores. (Donepezil Fig10)
A line graph comparing the cumulative percentage of patients versus ADCS-ADL change from baseline for Donepezil Hydrochloride 10 mg/day and placebo. The x-axis represents ADCS-ADL change from baseline, ranging from positive to negative values; the y-axis shows cumulative percentage of patients from 0% to 100%. Two curves illustrate patient response distribution for the drug and placebo groups.*
FDA Label Image

Figure 11. Time-course Of The Change From Baseline In Sib Score For Patients Completing 24 Weeks Of Treatment. (Donepezil Fig11)

Figure 11. Time-course Of The Change From Baseline In Sib Score For Patients Completing 24 Weeks Of Treatment. (Donepezil Fig11)
A line graph comparing the least squares mean change in SIB score from baseline over 24 weeks of drug treatment for Donepezil Hydrochloride at 10 mg/day and 23 mg/day doses. The y-axis represents SIB change from baseline, showing clinical improvement and decline, while the x-axis represents weeks of treatment. Error bars indicate standard error around the means.*
FDA Label Image

Figure 12. Cumulative Percentage Of Patients Completing 24 Weeks Of Double-blind Treatment With Specified Changes From Baseline Sib Scores. (Donepezil Fig12)

Figure 12. Cumulative Percentage Of Patients Completing 24 Weeks Of Double-blind Treatment With Specified Changes From Baseline Sib Scores. (Donepezil Fig12)
A cumulative percentage of patients line graph comparing Donepezil Hydrochloride 10 mg/day and 23 mg/day. The x-axis shows SIB change from baseline with negative values indicating improvement, and the y-axis shows cumulative percentage of patients from 0 to 100%. Two curves representing the two dosage groups show the distribution of patient responses over the SIB change range.*
FDA Label Image

Figure 13. Frequency Distribution Of Cibic-plus Scores At Week 24. (Donepezil Fig13)

Figure 13. Frequency Distribution Of Cibic-plus Scores At Week 24. (Donepezil Fig13)
A bar chart comparing percentages of patients rated by CIBIC-plus scale for Donepezil Hydrochloride at 23 mg/day and 10 mg/day doses. The x-axis shows CIBIC-plus rating categories from markedly improved to markedly worse, and the y-axis displays the percentage of patients in each category.*
FDA Label Image

Figure 2. Cumulative Percentage Of Patients Completing 24 Weeks Of Double-blind Treatment With Specified Changes From Baseline Adas-cog Scores. The Percentages Of Randomized Patients Who Completed The Study Were: Placebo 80%, 5 mg/day 85%, And 10 mg/day 68%. (Donepezil Fig2)

Figure 2. Cumulative Percentage Of Patients Completing 24 Weeks Of Double-blind Treatment With Specified Changes From Baseline Adas-cog Scores. The Percentages Of Randomized Patients Who Completed The Study Were: Placebo 80%, 5 mg/day 85%, And 10 mg/day 68%. (Donepezil Fig2)
A cumulative percentage graph displaying patients' change from baseline in ADAS-cog scores for placebo, donepezil hydrochloride 5 mg, and 10 mg/day treatment groups. The x-axis shows change from baseline, and the y-axis shows the cumulative percentage of patients. The chart includes annotations for points indicating no change and a table summarizing percentages of patients across treatment groups at different score changes (-7, -4, 0, 2, 8).*
FDA Label Image

Figure 3. Frequency Distribution Of Cibic-plus Scores At Week 24. (Donepezil Fig3)

Figure 3. Frequency Distribution Of Cibic-plus Scores At Week 24. (Donepezil Fig3)
Bar chart showing the distribution of patient percentages across categories of CIBIC-plus ratings for Donepezil Hydrochloride 10 mg/day, 5 mg/day, and placebo groups. Categories range from Markedly Improved to Markedly Worse, with data comparing treatment effects on patient outcomes.*
FDA Label Image

Figure 4. Time-course Of The Change From Baseline In Adas-cog Score For Patients Completing The 15-week Study. (Donepezil Fig4)

Figure 4. Time-course Of The Change From Baseline In Adas-cog Score For Patients Completing The 15-week Study. (Donepezil Fig4)
A line graph showing the ADAS-cog change from baseline over 15 weeks of drug treatment comparing Donepezil Hydrochloride 10 mg/day, 5 mg/day, and placebo. The vertical axis shows mean change ± standard error, with improvement above baseline and decline below. The 10 mg/day group shows greater clinical improvement over time compared to the 5 mg/day and placebo groups, which show less improvement or decline.*
FDA Label Image

Figure 5. Cumulative Percentage Of Patients With Specified Changes From Baseline Adas-cog Scores. The Percentages Of Randomized Patients Within Each Treatment Group Who Completed The Study Were: Placebo 93%, 5 mg/day 90%, And 10 mg/day 82%. (Donepezil Fig5)

Figure 5. Cumulative Percentage Of Patients With Specified Changes From Baseline Adas-cog Scores. The Percentages Of Randomized Patients Within Each Treatment Group Who Completed The Study Were: Placebo 93%, 5 mg/day 90%, And 10 mg/day 82%. (Donepezil Fig5)
A cumulative percentage of patients graph showing change from baseline on the x-axis and cumulative percentage of patients on the y-axis. The graph compares three groups: Donepezil Hydrochloride 10 mg/day, 5 mg/day, and placebo, illustrating their respective treatment effects with reference points at 7 and 4 points improvement and no change. A table within the graph summarizes the percentage of patients achieving significant changes in ADAS-cog scores for each treatment group.*
FDA Label Image

Figure 6. Frequency Distribution Of Cibic-plus Scores At Week 12. (Donepezil Fig6)

Figure 6. Frequency Distribution Of Cibic-plus Scores At Week 12. (Donepezil Fig6)
A bar chart showing CIBIC-plus ratings depicting the percentage of patients across different categories from markedly improved to markedly worse. The chart compares three groups: Donepezil Hydrochloride 10 mg/day (black bars), 5 mg/day (gray bars), and placebo (white bars), illustrating patient response distributions for each treatment group.*
FDA Label Image

Figure 7. Time Course Of The Change From Baseline In Sib Score For Patients Completing 6 Months Of Treatment. (Donepezil Fig7)

Figure 7. Time Course Of The Change From Baseline In Sib Score For Patients Completing 6 Months Of Treatment. (Donepezil Fig7)
A line graph illustrating SIB (Severe Impairment Battery) change from baseline over 6 months of drug treatment. The graph compares Donepezil Hydrochloride 10 mg/day to placebo, showing mean change with standard error. The Donepezil group shows clinical improvement, while the placebo group shows clinical decline over time.*
FDA Label Image

Figure 8. Cumulative Percentage Of Patients Completing 6 Months Of Double-blind Treatment With Particular Changes From Baseline In Sib Scores. (Donepezil Fig8)

Figure 8. Cumulative Percentage Of Patients Completing 6 Months Of Double-blind Treatment With Particular Changes From Baseline In Sib Scores. (Donepezil Fig8)
A cumulative percentage plot comparing patients treated with Donepezil Hydrochloride 10 mg/day and placebo. The x-axis represents SIB change from baseline, showing negative values, while the y-axis shows the cumulative percentage of patients from 0 to 100%, illustrating response distributions for each group with distinct curve markers.*
FDA Label Image

Figure 9. Time Course Of The Change From Baseline In Adcs-adl-severe Score For Patients Completing 6 Months Of Treatment. (Donepezil Fig9)

Figure 9. Time Course Of The Change From Baseline In Adcs-adl-severe Score For Patients Completing 6 Months Of Treatment. (Donepezil Fig9)
A line graph showing the change from baseline in ADCS-ADL scores over 6 months of drug treatment. It compares Donepezil Hydrochloride 10 mg/day to placebo, with the y-axis representing mean change from baseline and the x-axis indicating months of treatment. The graph includes error bars and labels indicating clinical improvement and decline.*
FDA Label Image

Chemical Structure (Donepezil Str)

Chemical Structure (Donepezil Str)
Chemical structure of Donepezil Hydrochloride, showing its molecular framework including methoxy groups, piperidine ring, and benzyl components, along with the associated hydrochloride (HCl) moiety.*
FDA Label Image

Label (Lbl713352436)

Label (Lbl713352436)
Donepezil Hydrochloride Tablets, USP 10 mg oral tablets, in a 30-count package. The label shows NDC 71335-2436-1 and states the product is repackaged by Bryant Ranch Prepack, Inc., Burbank, CA, and manufactured by ACI HealthCare Limited. Storage instructions specify room temperature conditions. The label includes barcodes and a QR code.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.